![Illumina’s NovaSeq Platform, the $100 Human Genome & Moore’s Law: is it Good Business?](https://evolution-bio.com/wp-content/uploads/2017/01/170110-illumina-novaseq-bio.jpg)
At the JP Morgan Conference on Monday, Illumina took the opportunity showcase its new DNA sequencers, the NovaSeq 5000 and NovaSeq 6000, promising that by the end of the year
![Evolution M&A Analysis: Evaluating Potential Acquisition Targets for Thermo Fisher Scientific](https://evolution-bio.com/wp-content/uploads/2016/03/160216-thermo-acquisition-targets.jpg)
A recent mixed securities shelf registration filing by Thermo Fisher Scientific has prompted speculation from industry insiders and investors, with prominent advisors predicting further acquisitions for the company throughout 2016
![To CRISPR or not to CRISPR: The Ongoing Ethical Debate Surrounding Embryonic Gene Editing](https://evolution-bio.com/wp-content/uploads/2016/02/160202-crispr-debate.jpg)
The UK’s Human Fertilisation and Embryology Authority (HFEA) has given the go-ahead for a select group of Francis Crick Institute researchers to edit the genomes of human embryos. The group,
![Evolution M&A Analysis: Thermo Fisher to Acquire Affymetrix for $1.3 billion](https://evolution-bio.com/wp-content/uploads/2016/04/160112-thermo-affymetrix.jpg)
Thermo Fisher Scientific (NYSE:TMO) have announced an agreement to acquire Affymetrix (NASDAQ:AFFX) for approximately $1.3 billion, or $14.00 per share, in cash. The acquisition was unanimously approved by the boards
![The Role of Metagenomic Analysis in Drug Development](https://evolution-bio.com/wp-content/uploads/2016/04/genomic_sequencing_usamriid.jpg)
In recent years Next Generation Sequencing instrumentation has become much more accurate, efficient and affordable, enabling researchers to collect, sequence and analyse genomes with increasing ease. Consequently researchers are developing
![Researchers Announce ViroCap Test Capable of Detecting Nearly All Infectious Viruses](https://evolution-bio.com/wp-content/uploads/2016/04/151021-virocap-virus.jpg)
Last month researchers at Washington University in St. Louis announced the ongoing development of ViroCap, a novel test capable of detecting nearly all viruses known to infect humans and animals.
![Thermo Fisher and Illumina Prepare for Round Two of the Next-Gen Sequencing Battle](https://evolution-bio.com/wp-content/uploads/2016/04/150916-news-ions5.jpg)
Earlier this month Thermo Fisher Scientific announced the launch of two novel next-generation sequencing (NGS) instruments, the Ion S5 and the Ion S5 XL benchtop systems, which combine the ability
![Evolution Announce Human Capital Partnership with Genomics Startup QuantiHealth](https://evolution-bio.com/wp-content/uploads/2016/04/150909-news-quanti-zhao.jpg)
Evolution Global Talent Attraction recently signed a contract to provide human capital to newly formed company QuantiHealth in China. QuantiHealth was founded by Zhao Bowen, who was named as one
![Bio-Rad Reports Strong Fourth-Quarter and Full-Year 2014 Financial Results](https://evolution-bio.com/wp-content/uploads/2016/04/blog-biorad-results.jpg)
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, announced financial results today for the fourth quarter and fiscal year ended
![23andMe and Genentech Announce Research Partnership](https://evolution-bio.com/wp-content/uploads/2016/04/chromosomes-blue.jpg)
Controversial DNA sequencing company 23andMe announced the first of 10 deals to be signed with large biotech and pharma firms on Tuesday January 6. Their $60 million partnership with Genentech
Illumina Reports Record Financial Results for Third Quarter of Fiscal Year 2014 Illumina, Inc. announced its financial results for the third quarter of 2014. Third quarter 2014 results: Revenue of